Tumors that occur in the thyroid gland as a result of lymph or vascular spread from distant sites are con sidered to represent meta static disease rather than a direct extension of a prim ary from an adjacent orga n. Met astatic deposits are identified at a higher frequ ency in abnor mal glands-that is, those with ade noma toid nodu les, thyroiditis, and follicular neopl asms. Further, metastatic dep osits may be fo und within pri mary thy roid tum ors, such as a ren al cell ca rcinoma metastatic to a thyro id papill ary carcinoma. Alth ough a thyroid gland mass may be the presentin g clinical sign, it is more often the underl ying thyroid gland disease (e.g., thyroiditis, ade nomatoid nodules) that prompts clini cal eva luatio n. Th e thyroid gland metastatic deposit is the initial presentation of an occ ult prim ary tumor in as many as 40% of pati en ts. Carcinoma s are the most common meta static tum ors from (in ord er of frequency) the kidney (figure I ), lung, breast (figure 2), and stomach; melanoma is less co mmo n.
The followingtreatment-relatedadverseevent swereeach reported in a singlepatient:tympano stomytube blockage; ear pruritus; tinnitus; oral moniliasis; crying; dizz iness; anderyt hema. Acut e Oti tis Extern a:The followingtreatment-related adverseevents occurredin0.4% or more ofthe patients with intacttymp ani c membranes.
Pregnancy
Teratogeni c Eff ects. PregnancyCat egory C: Reproductionstudieshave been performe d inratsandmice using oral dosesof up to 100 mgl kg and IV dosesup to 30 mgl kg and have revealed no evidence of harm to the fetus as a resul t of ciprofloxacin. In rabbi ts, ciprofloxacin 13 0 and 100 mglkg orally} produced gastrointestinal disturba nces resulting in maternal weight loss and an increase d incidenceof abortion, but no teratogenicity was observed at eithe r dose. After intrave nous adm inist rati on of doses upto 20 mg/kg, no maternal toxicitywas prod uced in the rabbit, and no embryotoxicity or teratogen icitywas observed. Corticosteroids are generallyteratogenic in laboratory animals when admi nistered systemicallyat relatively low dosa gelevels. The more potent corticosteroids havebeenshownto be teratogeni c after dermal application in laboratoryanimals.Animal reprodu ction stu dies have not been conducted with CIPROD EX1.l Otic. Noadequ ate andwellcontroll edstudies have beenperformed in pregnantwomen. Caution shouldbe exercised when CIPRD DEX' Otic is used by a pregnant woman. NursingMothers:Ciprofloxacinand corti costeroids, asa class, appear in milkfollowing oral admi nistration. Dexamethasone in breast mil k could suppress growt h, interfere with endogenous corticosteroid production, or cause otheruntoward effects. It is not knownwhether topi cal otic administration of ciprolloxacin or dexamethasone coul d result in sufficient systemic abso rption to produce detectable quantities in hum an mi lk. Because of the pot ential for unwanted effectsin nursinginfants, a decisionshould be made whether to discontinue nursing or to discontinue the drug,taking into accountthe importance of the drug to the mother. Pediatric Use: The safety and efficacy of CIPRODEX" Oti c have been established in pediatr ic patients 6 months and older1937patients)in adequate andwell-controlledclinical trials. Althoughnodataare available on patients lessthanage6 months, thereare noknown safety concerns or differences inthedisease processin this popul ationthat would preclude use of this product.(See DOSAGE ANDADMINISTRATION.) No clinically relevant changes inhearingfunction were observedin69 pedi atric patients(age4to12years) treated with CIPRO DEX' Otic andtested for audiometric parameters. ADVERSE REACTIONS In Phases II and III clinical trials, a total of 937 patients were treated with CIPRDDEX" Otic. This included 400patients with acute otitismedia with tympanostomy tubes and 537 patients with acute otitis externa. The reportedtreat ment-related adverse events are listed below: Acute Otitis Media in pediatric patients with tympanostomy tubes: The following treatment-related adve rseeventsoccurred in0.5% or more ofthepatientswith non-intact tympanicmembranes.
The foll owing treatment-related adverse eventswere each reported in a single patient: ear discomfort; decreased hearing; and ear disorder (tingling).
DOSAGE ANDADMINISTRATION
CIPRDDEX" OTIC SHOULD BESHAKEN WEll IMMEDIATELY BEFORE USE CIPRDDEX' Otic contains 3 mglmL 13000~g l m L) ciprofloxacin and 1 mgl mL dexamet hasone. Acute Otiti s Mediain pediatric patients withtympanostomytubes:The recommended dosage regi menfor the treatment of acute otitis media in pediatric patients lage 6 months and older) through tympanostomy tubes is: Four drops 10.14mL,0.42 mg ciprofloxacin,0.14 mgdexamethasone)instilled intothe affected ear twice daily for seven days.The solution should be warmed by holding the bottle in the handfor one or two minutes to avoiddizziness, which may result fromthe instill ation of a cold solution. The pati ent should lie with the affected ear upward, and then the drops should be instilled. The tragus should then be pumped 5 times by pushing inward to facili tate penetration of the drops into the middle ear. This positionshould be mai ntained for 60 secon ds. Repeat, if necessary, for the opposi te ear. Discard unu sed porti on after therapy is completed.Acute Otiti s Extern a:The recommendeddosage regimen for the treatmentof acute otitis externa is: For patients lage 6 months and older):Four drops (0.14 ml , 0.42 mg ciprofloxacin, 0.14 mg dexamethasone) instilled into the affected ear twice daily for sevendays. The solution should be warmed by holding the bottle inthe hand for one ortwominutesto avoid dizziness, which may result from theinsti llationof a cold solution. The patientshould lie withthe affec ted ear upward, andthenthe drops should be instilled.Thispositionshouldbe maintainedfor 60secondstofacili tate penetrationof the drops intothe ear canal. Repeat, if necessary, for the opposite ear. Discard unused portion after therapy is completed.
HOWSUPPLIED
CIPRDD EX"lciprofloxacin 0.3% and dexamethasone 0.1%) Sterile Otic Suspension is supplied as follows: 5 mL fill and 7.5 ml fill in a DRDP-TAINER' system. The DROP-TAINER' system consists of a natural polyethylene bottle and natural plug, with a white polypropylene closure. Tamper evidence is provided with a shrink band around the closure and neck area of the package. NDC 0065-8533-01, 5 mL fill; NDC 0065-8533-02,7 .5mLfill. Storage: Store at controlled roomtemperature, 15°Cto 30°C159°Fto 86°F). Avoi d freezing. Protect fromlight. Clinical Studies: In a randomized, multicenter, controlled clinical trial, CIPRD DEX· Otic dosed 2 times per day for 7 days demon strated clinical cures in the per protocol analysis in 86% of ADMT patients compared to 79% for ofloxacin solution, 0.3%, dosed 2 times per day for 10 days. Among culture positive patients, clinical cures were 90% for C I P R O D EX~Otic comp ared to 79% for ofloxacin solution, 0.3%. Microbiological eradication rates for these patients in the same clinical trial were 91% for CIPRODEX' Otic compared to 82% for ofloxacin solution, 0.3%. In 2 randomized multicenter, controlled clinical trials, CIPRODEX ' Otic dosed 2 times per day for 7 days demonstrated clinical cures in 87% and 94% of per protocol evaluable AOE patients, respectively. compared to 84% and 89%, respectively, for otic suspension containing neomycin 0.35%, polymyxin B 10,000 IUlmL, and hydrocortis one 1. 0% (neo/poly/HC).Amongculture pos itive patients clinic al cures were 86% and 92% for CIPRODEX' Otic compared to 84% and 89%,respectively, for neol polylHC. Microbiological eradication ratesfor thesepatients in the same clinical trials were 86% and 92%for CIPRODEX' Otic compared to 85% and 85%, respectively, for neol polyl HC.
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1.CIPRD DEX' Otic packageinsert. Sodium hydroxide or hydrochloric acid maybe added for adjustment of pH. Ciprofloxacin, a fluoroquinolone is available as the monohydrochloride monohydrate salt of t -cvclopropyl-6-f1uoro-1. 4-dihydro-4-oxo -7-ll-piperazinyl)-3-quinolinecarboxylic acid. The empirical formula is C17H18FN3DJ-HCI·H2D. Dexamethasone, 9-fluoro-l l1beta),17,2 1-trihydroxy-16(alpha)-methylpregna-1, 4-diene-3,2 0-dione , isan anti-inflarnmatorv cort icosteroid. The empirica l formula isC22H29FOS.
2.Wolters Kluwer,SourcePrescriber

CLINICAL PHARMACOLOGY
Pharmacokinetics: Foll owing a single bilateral4 -drop (total dose= 0.28 ml , 0.84mg ciprofloxacin,0.28 mg dexamethasone) topical otic dose of C IPRO O E X~Otic topediatricpatients after tym panostomy tube insertion, measurable plasma concentrations of ciprofloxacin and dexamethasone were observed at 6 hours following administration in 2 of9 patientsand 5 of9 patients, respectively. Mean ± 50 peak plasma concentrations of ciprofloxaci n were 1. 39 ± 0.880 nglmL In=9). Peak plasma conce ntrati ons ranged from 0.543 ng/mL to 3.45 ng/mL and were on average approxi mately 0.1% of peak plasma concentrations achieve d with an oral dose of 250-mglSI. Peak plasma concentrations of ciprofloxacin were observed within 15minutes to 2 hours post doseapplication . Mean ± SOpeak plasma concentrations of dexamethasonewere 1.1 4 ± 1. 54 ng/mL(n=9). Peak plasmaconcentrationsranged from 0.135 ng/mL to 5.10ng/mLand were on average approximate ly 14% of peak concentrationsreported in the literatu re foll owing an oral O.5-mg tablet dose'", Peak plasma concentrations of dexamethason e were observe dwithin 15 minutesto 2 hours post dose app lication. Dexamethasone has beenaddedto aidinthe resolution of the inflamm atory response accompanyi ngbacterial infection (such as oto rrheain pediatric patients with AOM with tympanostomytubes).
Microbiology: Ciprofloxacin has invitro activityagai nsta widerange of gram-positive and gram-negative microo rgan isms. The bactericidal action of ciprofloxacinresul ts from interference with the enzyme, DNA gyrase, whic h is neededfor the synthesis of bacterial DNA. Cro ss-resistance has been obse rved between ciprof loxac in andother fluoroquinolones. There is generally no cross-resistance between ciprofloxacin andother classes of antibacterial agentssuch as beta-lactarnsoraminoglycosides.
Ciprofloxacin has been shown to be active aga instmost isola tes of the following microorganisms, both in vitroand clinically in otic infections as describedin the INDICATIONS ANDUSAGE section.
Aerobic and facultative gram-positive microor ganisms: Staphylococcus aureus, Streptococcus pneumoniae. Aerobic and facult ative gram-negative microorganisms: Haemophilus influenzae, Moraxell a catarrhalis, Pseudomonas aeruginosa.
INDICATIONS ANDUSAGE: CIPRODEX' Otic is indicated for the treatment of infections caused by suscepti ble isolates of the designated microorganisms in the specific conditions listed below: Acut e Ot itis
Media in pediatric patients l age 6 months and older) with tympanostomy tubes due to Staphylococcus
aureus, Streptococcus pneumoniae , Haemophilus influenzae, Moraxella catarrhalis, and Pseudomonas aeruginosa. Acute Otitis Externa in pediatric (age6 month s and older). adult and elderly patient s dueto Staphylococcusaureusand Pseudomonas aeruginosa.
CDNTRAINDICATIDNS
CIPR ODEX@Otic is contraindicated in patientswith a history of hypersensi tivity to ciprofloxacin,to other quinolones, orto anyofthe compon ents inthismedication. Use of thisproduct is contraindicated inviral infections of theexternal canal including herpes simplexinfections.
WARNINGS FOR OTIC USE ONLY IThis product is not approved for ophthalmic use.} NOTFOR INJECTION CIPRDDEX' Oticshould be discontinued at the first appearance of a skin rash or any other sign of hypersensit ivity. Serious and occas ionally fatal hypersensi tivity (anaphylactic) reactions, some following the first dose, have been reported in patients receiving systemi c quinolones. Serious acute hypersensitivity reactions mayrequire immediate emergency treat ment.
PRECAUTIONS
General: Aswith otherantibacterial preparations,useof thisprod uct mayresult inovergrowth of nonsusceptibleorga nisms,including yeast andfungi. If theinfection isnotimprovedafter one weekof treatment, culturesshouldbe obtainedto guidefurther treatment.If otorrheapersists after a full courseoftherapy, or if two ormore episo desof otorrhea occurwithin sixmonths, further evaluationisrecomme nded to exclude an underl ying condition such as cholesteatoma,foreign body, or a tumor. The syste mic administration of quinolones. includin g ciprofloxac in at doses much higher than given or abso rbed by the otic route, has ledto lesions or erosions of the carti lagein weight-bea ring joints and oth er signs of arthropathy in immature animals of various species. Guinea pigs dosed inthe mid dle ear with C I P RO D E X~Otic for one month exhibited nodrug-related structural or functional changes of the cochl earhair cellsandno lesions in the ossi cles. C I P R O D EX~Otic was also shown to lack dermal sensit izing potential in the gui nea pig when tested accordingto the method of Buehler. No signsof local irritation were found when CIPRODEX® Otic was applied topically in the rabbit eye. Information for Patients: For otic use only. (This product is not approved for use inthe eye. ) Warmthe bottle in your hand for one to two minutes pri or to use and shake well immediatelybefore using. Avoid conta minatingthe tip with material fromthe ear,fingers, or other sources. Protect from light. If rash or allergic reaction occurs, discontinue use immediatelyand contact your physicia n. It is very importantto use the ear drops for as long as the doctorhas instructed, even if the symptoms improve. Discard unusedportionaftertherapyis completed.Acute Otitis Medi a inpediatric patients with tymp anostomy tubes: Prior to adm inistration of CIPROD EX®Ot ic in patients (6 months and older) with acute oti tis media through tympanostomy tubes, the solution should be warmed by holding the bott le in the hand forone ortwo minut es to avoid dizziness which may resul t from the instillationof a 
Adverse Event
Incidence ( sepa ration between primary and metastatic tumors; primary thyroid fo llicular tum ors will usually be imm unoreactive with thyroglobul in, CK7, and TTF -l , while C-cell-der ived tumors will be reacti ve to calci ton in and chro mogra nin. With incre dibly rare exce ptio n, metastatic tumor s will not be thyroglob ulin-re active. Th e prognosis of a patient with a tumor metastatic to the thyroid is determined by the und erlying primary, but in most cases it is poor. However, if metastatic disea se is lim ited to the thyroi d gland, surgery can pro long survival.
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